Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of AMX0035 in Adult Patients with Amyotrophic Lateral Sclerosis
2021-000250-26Phase 3Active
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoint: ALSFRS-R change and survival over 48 weeks. Started Jun 2021; status: active.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-000250-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000250-26.